Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech To Use Upside From Avastin For Incremental R&D, SG&A Spend

This article was originally published in The Pink Sheet Daily

Executive Summary

The oncologic generated sales of $38.1 mil. during the first five weeks on the market. Genentech has raised its earnings guidance to 20% to 25% for the year.

You may also be interested in...



Avastin Account Orders Double, Reorder Rate Improves To 80%

The number of accounts ordering the oncologic rose from 1,500 to more than 3,000 in the second quarter, with 80% of accounts placing reorders. Genentech says the majority of Avastin's sales come from the front-line setting.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

Topics

UsernamePublicRestriction

Register

PS059336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel